Daniel Gold, MEI Pharma CEO (via website/Vimeo)
As FDA door shuts on its PI3K, MEI Pharma throws in the towel, lays off staff
Having steered a PI3K inhibitor from preclinical studies all the way to Phase II, San Diego’s MEI Pharma is all but washing its hands of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
